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ABSTRACT:
The Forkhead box P3 (FOXP3) transcription factor is the key driver of regulatory 
T cell (Treg cells) differentiation and immunosuppressive function. In addition, FOXP3 
has been reported to be expressed in many tumors, including melanoma. However, 
its role in tumorigenesis is conflicting, with both tumor suppressive and tumor 
promoting functions described. The aim of the current study was to characterize 
the expression and function of FOXP3 in melanoma. FOXP3 expression was detected 
by immunohistochemistry (IHC) in 12% (18/146) of stage III and IV melanomas. 
However expression was confined to fewer than 1% of cells in these tumors. 
Stable over-expression of FOXP3 in the SK-MEL-28 melanoma cell line reduced 
cell proliferation and clonogenicity in vitro, and reduced xenograft growth in vivo. 
FOXP3 over-expression also increased pigmentation and the rate of apoptosis of SK-
MEL-28 cells. Based on its infrequent expression in human melanoma, and its growth 
inhibitory and pro-apoptotic effect in over-expressing melanoma cells, we conclude 
that FOXP3 is not likely to be a key tumor suppressor or promoter in melanoma.
INTRODUCTION
The FOXP3 transcription factor regulates the 
lineage-specific differentiation of regulatory T cells (Treg 
cells), a subset of CD4+ T cells crucial for the maintenance 
of immune homeostasis. FOXP3 expression was originally 
thought to be restricted to Treg cells [1], however recent 
studies have suggested that FOXP3 is also expressed in 
multiple normal tissues, as well as in a number of tumor 
types. Specifically, FOXP3 expression has been reported 
in normal breast, prostate and ovarian epithelium, and 
to be down-regulated in the corresponding tumor tissue 
[2-4]. Conversely, increased FOXP3 expression has been 
reported in pancreatic adenocarcinoma [5], melanoma [6-
8], hepatocellular carcinoma [9], leukemia [10], bladder 
cancer [11], thyroid carcinoma [12] and cervical cancer 
[13], with no expression in corresponding normal tissue. 
These findings suggest either a pro- or anti-tumorigenic 
role, depending on the tumor type.
Several additional lines of evidence suggest a tumor 
suppressor role for FOXP3 in certain tumor types. First, 
FOXP3 represses expression of the HER2, Skp2, SATB1 
and MYC oncogenes [2, 3, 14, 15], and induces expression 
of the tumor suppressor genes p21 and LATS2 in breast 
and prostate cancer cells [16, 17]. FOXP3 has also been 
shown to repress BRCA1-mediated DNA repair and to 
promote DNA damage-induced apoptosis [18]. Second, 
over-expression of FOXP3 in glioma, breast, prostate 
and ovarian cancer cell lines induces profound growth 
inhibition in vitro and in vivo [2-4, 19]. Finally, somatic 
inactivating mutations of FOXP3 have been reported in 
breast and prostate cancers [2, 3], although notably these 
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findings were not confirmed by recent whole genome 
sequencing studies of these tumors [20]. In addition, 
our group did not identify any mutations in FOXP3 in a 
panel of 54 early passage melanoma cell lines or well-
established breast and prostate cancer cell lines [21]. 
In contrast, FOXP3 has also been suggested to 
facilitate tumorigenesis by enabling tumor cells to evade 
anti-tumor immunity. This has been demonstrated in 
pancreatic carcinoma and melanoma cell lines, where 
FOXP3 expression inhibits T cell proliferation in co-
culture systems [5, 8]. FOXP3 expression in tumors was 
also shown to be associated with worse overall survival in 
breast, bladder, and colorectal cancer patients [11, 22, 23]. 
We previously demonstrated FOXP3 expression in 
human melanoma tissue and cell lines [6], although the 
frequency of its expression was not assessed in a large 
cohort of cases. In addition, whether FOXP3 promotes or 
inhibits the growth of melanoma cells is unknown. The 
objectives of this study were to evaluate the frequency 
of FOXP3 expression in metastatic melanoma, and to 
determine its role in regulating the growth and survival of 
melanoma cells. 
RESULTS
FOXP3 expression is infrequent in advanced-
stage melanoma
We previously reported FOXP3 expression in 
human melanomas by demonstration of co-staining of 
FOXP3 with the melanoma cell surface antigen Melan-A 
[6]. However, this analysis did not quantify the percentage 
of melanomas which express FOXP3, or the percentage of 
FOXP3 positive cells within a tumor. To address this, we 
Figure 1: FOXP3 expression in advanced-stage melanoma. (A) Distribution of FOXP3 expression in 146 stage III and IV 
melanomas. (B) Representative image of FOXP3 staining in a melanoma sample using the anti-FOXP3 Ab10563 antibody or IgG isotype 
control antibody (bottom right panel). Tumor cells with large irregular-shaped nuclei are indicated with red arrows while Treg cells with 
smaller, denser nuclei are indicated with green arrows. (C) Staining of melanomas and cultured melanocytes with anti-FOXP3 Ab20034 
(clone 236A/E7) antibody. Sections were double-stained with anti-FOXP3 (brown) and anti-CD3 (Ferrangi blue) (left panel) or IgG isotype 
control antibodies (right panel) to distinguish between FOXP3 expressing tumor cells and infiltrating T cells. (D) Detection of FOXP3 
mRNA expression in a panel of human melanoma cell lines using quantitative real-time PCR.
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performed immunohistochemical staining for FOXP3 on 
a tissue microarray (TMA) comprising tumors from 146 
patients with stage III and stage IV metastatic melanoma, 
using the rabbit polyclonal anti-FOXP3 antibody 
Ab10563, directed against the C-terminus of FOXP3. 
Tumor cells and lymphocytes were distinguished based on 
the morphology of the stained cells (Figure 1A&B). This 
analysis demonstrated that 18/146 (12%) of advanced-
stage melanomas contained FOXP3 positive tumor cells. 
Quantification of the frequency of FOXP3 positive cells 
showed this to range between 0.3 and 7.5 positive cells per 
1000 tumor cells (0.03-0.75%). To validate these findings 
using an independent antibody, five of the FOXP3-
positive tumors were stained with the mouse monoclonal 
anti-FOXP3 antibody Ab20034 (clone 236A/E7, directed 
against amino acids AA107-AA196 of FOXP3). To 
further distinguish between melanoma cells and Treg 
cells, sections were co-stained with an anti-CD3 antibody. 
This analysis confirmed the findings obtained with the 
rabbit polyclonal antibody, with <1% of melanoma cells 
staining positive for FOXP3. Finally, we did not observe 
any FOXP3 staining in normal melanocytes cultured in 
vitro (Figure 1C).
We next examined FOXP3 mRNA expression in a 
Figure 2: Establishment of FOXP3 over-expressing melanoma cell lines. (A) Detection of FOXP3 expression following over-
expression in melanoma cell lines by staining with the anti-FOXP3 antibody (clone 236A/E7) and flow cytometry analysis. Blue solid 
lines represent FOXP3 expression in cells transfected with the pcDNA-empty vector and red dashed lines represent cells transfected 
with FOXP3. (B) Immunofluorescence staining of FOXP3 nuclear staining in a SK-MEL-28-FOXP3 clone. The anti-FOXP3 antibodies 
Ab20034 (a,b,c,d) and Ab10563 (e,f,g,h) were used to detect FOXP3 using Alexa-488 (green) and Alexa-555 (red)-conjugated secondary 
antibodies, respectively. FOXP3 nuclear staining is indicated by the red arrows. Panels i,j,k,h represents the cells stained with an IgG 
isotype control.  
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panel of 25 melanoma cell lines and in normal cultured 
melanocytes by quantitative PCR (QPCR). Low levels 
of FOXP3 mRNA (2-5 copies per 10,000 copies of beta-
actin) were detected in 16 of the 25 melanoma cell lines, 
representing expression 300- to 1000- fold lower than the 
level observed in Treg cells (2000 copies per 10,000 copies 
of beta-actin) (Figure 1D). Minimal level of FOXP3 was 
observed in normal melanocytes.
Effect of FOXP3 over-expression on melanoma 
cell growth
To directly determine the impact of FOXP3 on 
the growth of melanoma cells, we sought to manipulate 
FOXP3 levels in melanoma cell lines by RNAi 
knockdown and vector-mediated over-expression. Reliable 
down-regulation of FOXP3 in melanoma cell lines proved 
difficult to accurately evaluate due to its low basal level 
of expression (data not shown). We therefore sought to 
generate stable FOXP3 over-expressing melanoma cell 
lines, and twelve melanoma cell lines were chosen for 
transfection; LM-MEL-14, LM-MEL-17, LM-MEL-31, 
LM-MEL-34, LM-MEL-42, LM-MEL-45, LM-MEL-47, 
LM-MEL-53, LM-MEL-62, LM-MEL-73, SK-MEL-14 
and SK-MEL-28. For each cell line, transfection was 
performed in triplicate. Out of these 12 lines, we were able 
to establish stable G418 resistant clones from 9 of the lines 
(LM-MEL-17, LM-MEL-31, LM-MEL-34, LM-MEL-42, 
LM-MEL-45, LM-MEL-47, LM-MEL-62, SK-MEL-14 
and SK-MEL-28). However, eight out of the nine stably 
transfected melanoma cell lines demonstrated increased 
FOXP3 expression in <30% of cells (Supplementary 
Figure 1). SK-MEL-28 was the only cell line for which 
FOXP3 stable transfectants could be generated in which 
increased FOXP3 expression occurred in 64% of cells 
(Figure 2A). Nuclear FOXP3 expression was confirmed 
in this line by immunofluorescence (Figure 2B).
We next performed single cell cloning of the SK-
MEL-28-FOXP3 and SK-MEL-28-empty vector (EV) 
control lines in an attempt to control for intra-tumoral 
heterogeneity. Four independent SK-MEL-28-FOXP3 
and SK-MEL-28-EV clones were derived for further 
characterization. FOXP3 mRNA expression in the SK-
MEL-28-FOXP3 clones was 90- to 1100-fold higher than 
that in SK-MEL-28-EV control clones, with expression 
levels comparable to that of Treg cells (Figure 3A). 
FOXP3 protein expression in the SK-MEL-28-FOXP3 
clones was also assessed by Western Blot (Figure 3B), 
which confirmed significantly higher level of FOXP3 
Figure 3: Validation of FOXP3 over-expression in SK-
MEL-28 cells. (A) FOXP3 mRNA expression in four SK-
MEL-28-FOXP3 and SK-MEL-28-EV clones measured using 
quantitative real-time PCR. (B) FOXP3 protein expression in 
the same four SK-MEL-28-EV and SK-MEL-28-FOXP3 clones 
detected by Western Blot using the anti-FOXP3 (236A/E7) 
antibody. The expected protein size for myc-tagged FOXP3 is 
51kDa, and GAPDH is 38kDa.
Figure 4: Effect of FOXP3 over-expression in SK-
MEL-28 cells on melanoma cell pigmentation. (A) 
Increased pigmentation observed macroscopically in the four 
SK-MEL-28-FOXP3 clones compared to the SK-MEL-28-EV 
clones. (B) Expression of the melanoma-specific differentiation 
genes MLANA, TYR and TYRP1 in the four SK-MEL-28-
FOXP3 clones (red) and SK-MEL-28-EV clones (blue). Values 
shown are the mean and SEM of the four clones
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protein expression in SK-MEL-28-FOXP3 clones 
compared to SK-MEL-28-EV clones.
FOXP3 over-expression increases pigmentation 
and markers of melanocyte differentiation in SK-
MEL-28 melanoma cells 
After approximately five passages, we noted that 
the four SK-MEL-28-FOXP3 clones demonstrated 
increased pigmentation, whereas none of the four SK-
MEL-28-EV clones displayed this feature (Figure 4A). We 
therefore examined the expression of melanoma-specific 
differentiation genes including Melan-A (MLANA), 
Tyrosinase (TYR) and Tyrosinase-related protein 1 
(TYRP1) by quantitative PCR. Expression of these genes 
was significantly up-regulated (~2- to 9-fold) in FOXP3 
over-expressing compared to EV clones (Figure 4B). 
FOXP3 over-expression decreases proliferation of 
SK-MEL-28 melanoma cells
Three approaches were utilised to compare the 
proliferative rates of SK-MEL-28-EV and SK-MEL-
28-FOXP3 clones; cell counts, MTS assays and CFSE 
dye dilution experiments. For determination of cell 
Figure 5: Effect of FOXP3 over-expression in SK-
MEL-28 cells on melanoma cell proliferation and 
apoptosis. (A) Cell number. The four SK-MEL-28-EV and 
SK-MEL-28-FOXP3 clones were seeded at a density of 1x105 
cells/T75cm2 flask, and cell counts determined five days later. 
Each data point is the average of three independent experiments 
of the SK-MEL-28-FOXP3 clones (red) and the SK-MEL-28-
EV clones (blue). (B) Assessment of cell proliferation of the 
four SK-MEL-28-EV and SK-MEL-28-FOXP3 clones using 
the MTS assay. Values shown are the mean and SEM of a 
single representative experiment performed in triplicate. (C) 
Assessment of cell proliferation using the CFSE-Proliferation 
assay. SK-MEL-28-EV clones (blue dotted lines) showed lower 
CFSE staining intensity due to a greater number of divisions 
during the 6 day period compared to SK-MEL-28-FOXP3 
clones (red solid lines). (D) Graph represents the mean CFSE 
intensity (MFI) of the four SK-MEL-28-EV and SK-MEL-28-
FOXP3 clones at day 6 relative to day 0 (after labeling). (E) 
Basal apoptosis was determined in the four SK-MEL-28-EV and 
SK-MEL-28-FOXP3 clones by propidium iodide staining and 
flow cytometry.
Figure 6: Effects of FOXP3 over-expression on 
melanoma cell clonogenecity. (A) Colony formation of 
the four SK-MEL-28-FOXP3 and EV control clones grown on 
plastic. 1,000 cells were seeded in 150mm x 15mm petri dishes 
and colony formation monitored over 3 weeks. Macroscopic 
view of the colonies stained with 0.1% Crystal Violet (left panel) 
and the number of colonies (≥40 cells) counted (right panel). 
(B) Colony formation of the four SK-MEL-28-FOXP3 and EV 
control clones grown in soft agar for 3 weeks. Brightfield images 
of the colonies from four SK-MEL-28-EV and SK-MEL-28-
FOXP3 clones (left panel) and the number of viable colonies 
(≥40 cells) counted after staining with MTT (right panel). 
Values shown are the mean and SEM of a single representative 
experiment performed in triplicate.
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proliferation rates by cell counting, each clone was seeded 
at the same density and the number of cells counted after 
five days. Cell number was significantly higher after 5 
days in the SK-MEL-28-EV clones compared to the SK-
MEL-28-FOXP3 clones (p<0.01; Figure 5A). 
MTS colorimetric assays were subsequently 
performed over an eight day period to verify this finding 
(Figure 5B). At day 6 and 8 post-seeding, cell viability 
was significantly higher in the SK-MEL-28-EV clones 
compared to the FOXP3 over-expressing clones (p≤0.05). 
Finally, cells were stained with CFSE and the 
fluorescence intensity measured after 6 days. The mean 
intensity of CFSE staining was significantly lower in 
the four SK-MEL-28-EV clones (blue dots) compared 
to the SK-MEL-28-FOXP3 clones (red dots), consistent 
with more frequent cell division in the SK-MEL-28-EV 
clones (p<0.05) (Figure 5C). Collectively, these findings 
demonstrate that FOXP3 over-expression slows the 
growth of melanoma cells.
FOXP3 over-expression increases apoptosis in 
SK-MEL-28 melanoma cells
As previous studies in glioma, breast, prostate 
and ovarian cancers demonstrated that FOXP3 over-
expression induces apoptosis [2-4, 19], we examined the 
effect of FOXP3 over-expression on apoptosis in SK-
MEL-28 melanoma cells. SK-MEL-28-FOXP3 and SK-
MEL-28-EV clones were stained with propidium iodide 
and the sub-diploid (apoptotic) fraction assessed by flow 
cytometry. The basal fraction of apoptotic cells was 3.8-
fold higher in SK-MEL-28-FOXP3 clones compared to 
the empty vector controls (Figure 5D). 
FOXP3 over-expression decreases clonogenecity 
of SK-MEL-28 melanoma cells
We next performed clonogenic assays on plastic 
and in soft agar to test for the ability of FOXP3 over-
expressing cells to grow under adherent and anchorage 
independent conditions, respectively. In adherent 
colony formation assays, SK-MEL-28-FOXP3 clones 
demonstrated a marked reduction in both the size and 
number of colonies compared to SK-MEL-28-EV clones 
(p<0.05) (Figure 6A). Likewise, the ability of SK-MEL-
28-FOXP3 clones to form colonies in soft agar was 
significantly reduced, with 8-fold fewer colonies observed 
in the SK-MEL-28-FOXP3 clones (Figure 6B).
FOXP3 over-expression reduces tumor growth in 
vivo
To validate the in vitro finding that FOXP3 over-
expression slows the growth of melanoma cells, a 
representative SK-MEL-28-FOXP3 clone with high 
FOXP3 expression and a representative SK-MEL-28-
EV clone were selected for assessment of growth in vivo. 
Equal numbers of cells from both clones were injected 
subcutaneously into Balb/c nude mice and tumors 
allowed to develop for 3 weeks. The growth rate of the 
SK-MEL-28-FOXP3 clone was significantly slower than 
that of the empty vector clone (Figure 7A). Consistent 
with this finding, resected SK-MEL-28-FOXP3 tumors 
had a significantly lower weight compared to SK-MEL-
28-EV control tumors (Figure 7B). FOXP3 expression in 
the tumors was determined by QPCR, which confirmed 
that the SK-MEL-28-FOXP3 clone retained expression of 
FOXP3 during this assay.
Microarray expression profiling of FOXP3 over-
expressing SK-MEL-28 melanoma cells
Lastly, to gain mechanistic insights into the 
molecular basis for FOXP3-mediated growth inhibition 
Figure 7: Assessment of growth of SK-MEL-28-EV 
and SK-MEL-28-FOXP3 clones as xenografts in vivo. 
(A) 9x105 cells from a representative SK-MEL-28-EV and SK-
MEL-28-FOXP3 clone were injected into BALB/c nude mice 
and tumor growth monitored daily by calliper measurements 
(n=5). (B) Validation of FOXP3 mRNA expression in the 
resected tumors by quantitative real-time PCR (QPCR) (right 
panel). (C) Images of resected tumors and (D) weight of the 
SK-MEL-28-FOXP3 and SK-MEL-28-EV tumors measured 
following resection after sacrifice. The values shown are the 
mean and SEM of the five tumors.
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and apoptosis, we used Illumina HT-12 gene expression 
microarrays to interrogate the transcriptomes of two SK-
MEL-28-FOXP3 and two SK-MEL-28-EV clones. FOXP3 
over-expression led to a clear and consistent difference in 
the gene expression profile, as demonstrated by separation 
of the SK-MEL-28-FOXP3 and SK-MEL-28-EV clones 
by hierarchical clustering (Figure 8A). We identified 204 
differentially expressed genes between the two groups 
when the percentage of false positives was limited to 
5% (Supplementary Table 2) (Figure 8B). Twelve of the 
differentially expressed genes were validated by QPCR, 
and all demonstrated the same differential expression 
pattern as that observed in the microarray (Supplementary 
Figure 2). FOXP3 was not found among the differentially 
expressed genes, as the FOXP3 probes on the HT-12 array 
target the FOXP3 3’ UTR which is not present in the 
expression vector. At the level of individual genes, one of 
the most highly up-regulated was MT1F (Metallothionein 
1F), a gene involved in cellular responses to a variety of 
stressors [24], suggesting that FOXP3 over-expression 
may be inducing cellular stress in these cells.
Notably, some of the differentially expressed genes 
with the greatest fold changes were members of the 
Cancer Testis Antigen gene families, which are known to 
be epigenetically regulated and aberrantly re-expressed 
in melanoma and other cancers [25]. In particular several 
GAGE family members were highly up-regulated, and 
several MAGE family members such as MAGEC1 
and MAGEA4 were highly down-regulated. Despite 
the differences in cell proliferation and apoptosis, no 
Figure 8: Gene expression profiling of SK-MEL-28-FOXP3 and SK-MEL-28-EV clones. (A) Hierarchical clustering of 
the entire unfiltered gene expression dataset effectively separated the SK-MEL-28-FOXP3 and SK-MEL-28-EV clones. (B) Hierarchical 
clustering of the 204 significantly differentially expressed genes.
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differential expression of typical regulators of proliferation 
and apoptosis was observed.
DISCUSSION
FOXP3 expression has been reported in a variety 
of normal and cancerous tissues outside of the Treg cell 
lineage, with two opposing expression patterns. On the 
one hand, FOXP3 expression has been reported to be 
widespread in the normal epithelium and tissue of the 
breast, prostate, ovary and brain, and down-regulated 
in matched tumor cells [2-4, 19, 26], although in mice, 
the level of Foxp3 mRNA expression in these tissues 
was shown to be approximately 100-fold lower than 
that in Treg cells [27]. Conversely, FOXP3 has been 
reported to be over-expressed in tumor cells in pancreatic 
adenocarcinoma, melanoma, leukemia, hepatocellular 
carcinoma, bladder cancer, thyroid carcinoma and cervical 
cancer [5, 6, 9, 11-13, 28]. 
In our previous study, we reported FOXP3 
expression in both metastatic melanoma tissue samples 
and cell lines derived from tumor samples [6]. Two other 
groups subsequently reported similar findings [7, 8]. Niu 
et al. [8] reported that FOXP3-expressing melanoma 
cells inhibited the proliferation of anti-CD3/anti-CD28-
activated T-cells through FOXP3-induced expression of 
T cell inhibitory molecules on melanoma cells (B7-H1 
and Fas ligand) and secreted immunosuppressive factors 
(TGF-β). Quaglino et al. [7] demonstrated a significant 
association between FOXP3 expression in primary 
melanomas and development of visceral metastases. 
However, none of these studies systematically addressed 
the percentage of melanomas which express FOXP3, or 
the percentage of FOXP3+ cells within melanomas. 
We found that 12% of stage III and IV metastatic 
melanomas expressed FOXP3 based on IHC staining of 
a tissue microarray. Furthermore, only a small population 
of cells within these tumors (<1%) expressed FOXP3 with 
nuclear localization. These results are in keeping with 
our previous study, where 6-colour flow-cytometry was 
used to analyse FOXP3 expression within disaggregated 
metastatic melanoma tissue. In this analysis, a distinct 
population of melanoma cells (identified as MCSP+ CD3- 
CD4- CD31- CD90-) expressing high levels of FOXP3 
was identified in some samples, with the frequency 
of these FOXP3bright cells ranging from 0 – 0.24% [6]. 
Interestingly, for most samples, we were also able to detect 
low-level FOXP3 expression in the bulk melanoma cell 
population, detected as a shift in fluorescence intensity 
compared to the fluorescence-minus-one (FMO) control. 
We hypothesise that the rare FOXP3bright cells in our 
previous study correspond to the rare FOXP3+ cells 
identified by IHC in the present study, whereas the low 
level FOXP3 expression observe in the bulk population 
by flow cytometry is below the detection limit of IHC. 
This low level expression is maintained by melanoma 
cell lines and can be detected at both the gene and protein 
level. However, we show here that this expression level 
is several orders of magnitude less than that observed in 
Treg cells.
The prevalence of FOXP3 staining within melanoma 
tissue sections in our IHC study is lower than that reported 
by Niu et al. [8] and Quaglino et al. [7], who reported 
abundant FOXP3 expression in both the nucleus and 
cytoplasm of melanoma tissue sections. An important 
difference in our studies is the FOXP3 antibodies used. 
While we used the anti-FOXP3 Ab20034 and Ab10563 
antibodies, the Niu and Quaglino studies used the anti-
FOXP3 PCH101 antibody [7, 8]. A number of recent 
publications have highlighted the importance of the 
antibody used in examining FOXP3 protein expression. 
For example, Tran et al. and Woo et al. reported that 
commercially available antibodies targeting different 
FOXP3 epitopes resulted in different staining patterns 
[29, 30]. The study by Tran et al. [29] also concluded 
that PCH101 was a less reliable indicator of FOXP3 
expression in human activated CD4+ T cells. In the study 
by Woo et al. [30], the anti-FOXP3 Ab20034 (clone 236A/
E7) antibody which was used in the current study was 
compared with the anti-FOXP3 Ab22510 antibody, and the 
authors concluded that more specific staining was obtained 
with Ab20034 in cervical intraepithelial neoplasia tissue 
sections. Finally, while FOXP3 expression has been 
reported in normal thymus as well as lung, ovarian, breast 
and prostate epithelium [2-4, 27], other studies have 
demonstrated otherwise, and attributed the differences to 
immunohistochemical staining artifacts [31-35]. While 
we did not directly compare the variation in staining 
of different FOXP3 antibodies in this study, these prior 
studies indicate that the 236A/E7 clone (Ab20034) is 
the most suitable antibody for IHC detection of human 
FOXP3 in both tumor and Treg cells. Based on our current 
findings generated using anti-FOXP3 antibodies Ab20034 
and Ab10563, we conclude that FOXP3 is expressed in 
12% of human metastatic melanomas with expression 
restricted to <1% of cells within these tumors. 
Given the low basal expression of FOXP3 in 
melanoma cell lines, our only means of assessing FOXP3 
function in these cells was to over-express the gene. 
Over-expression of FOXP3 in the SK-MEL-28 cell line 
increased the level of pigmentation and up-regulated 
expression of genes involved in pigment production 
(MLANA, TYR and TYRP1). Notably, these genes are 
targets of the micropthalmia-associated transcription 
factor (MITF), a key driver of melanocyte differentiation 
[36]. Expression of MITF however, was not significantly 
up-regulated following FOXP3 over-expression (data 
not shown). MITF has been shown to undergo post-
translational modifications that regulate its transcriptional 
activity [37-39]. A possibility therefore is that FOXP3 
over-expression leads to post-transcriptional modification 
of MITF and subsequent induction of MITF target genes.
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We also observed that FOXP3 over-expression 
markedly reduced the proliferation of SK-MEL-28 cells in 
vitro, reduced their ability to form colonies on plastic and 
in soft agar, and to grow as xenografts in vivo. These anti-
tumor effects of FOXP3 in melanoma cells are consistent 
with that previously reported in gliomas, breast, prostate, 
and ovarian cancer cells [2-4, 19]. FOXP3 has been 
shown to exert its growth inhibitory effect on breast and 
prostate cancer cells by transcriptionally repressing the 
expression of specific oncogenes (HER2, SKP2, SATB1 
and MYC) [2, 3, 14, 15], and inducing the expression of 
specific tumor suppressor genes (CDKN1A, LATS2) [16, 
17]. In our gene expression profiling experiments, we did 
not identify similar regulation of melanoma oncogenes 
and tumor suppressors or classical regulators of cell 
cycle and cellular senescence. Thus the mechanism by 
which FOXP3 inhibits growth of melanoma cells appears 
distinct.
SK-MEL-28-FOXP3 over-expressing clones also 
exhibited a higher basal rate of apoptosis. The specific 
mechanistic basis for this increased sensitivity is 
unknown, but could reflect the induction of cellular stress 
following FOXP3 over-expression. Re-expression of a 
gene out of context, for example in a cell lineage where it 
is not normally found, could disrupt normal homeostatic 
regulatory processes. This is particularly plausible in 
the case of transcription factors, where over-expression 
could change the expression of myriad other molecules, 
all of which could potentially perturb cellular function. 
Therefore, it is possible that over-expression of FOXP3 
and the subsequent modification of gene expression 
perturbed normal cell functions in melanoma cells, leading 
to induction of stress response pathways. For example, 
sustained stress of the endoplasmic reticulum and 
cytochrome c release due to over-production of random 
proteins results in collapse of mitochondrial membrane 
potential [40]. This possibility is supported by the 
observation that the classical stress-response gene MT1F 
is up-regulated in FOXP3 over-expressing cells.
The results of the present study, together with our 
previous report [6] reveal that FOXP3 is expressed at a 
high level in only a small fraction of melanomas, and in 
only a minor fraction of cells (<1%) within this subset of 
tumors. On the other hand, low level FOXP3 expression 
(likely below the limit of detection by IHC) is observable 
by flow cytometry and PCR in most freshly isolated 
melanoma specimens and in most melanoma cell lines. We 
propose that low level FOXP3 expression is advantageous 
to the tumor, possibly by providing immune suppressive 
function, in keeping with previous studies [5, 8, 11, 13, 
22]. In contrast, the results shown here clearly demonstrate 
that FOXP3 over-expression suppressed proliferation, 
increased differentiation and apoptosis and reduced 
tumorigenesis in vivo. Thus, tumor cells must carefully 
fine-tune their level of FOXP3 expression to balance 
these negative effects on growth against the putative 
positive effects of low level expression on immune escape, 
potentially explaining the conflicting reports regarding 
FOXP3 function in cancers. We propose that perturbing 




The LM-MEL-# melanoma cell lines [41] were 
generated from surgically excised melanoma as described 
previously [42]. Tissue donors provided informed consent 
for use of their tumor tissue in these studies and all 
protocols were approved by the Austin Health Human 
Research Ethics Committee, Melbourne Australia. 
Cell lines were maintained in complete RF10 medium 
which comprised RPMI-1640 supplemented with 2 mM 
Glutamax, 10mM HEPES, 100 units/mL penicillin/
streptoMYCin, (all from Life Technologies; Carlsbad, 
California, USA) and 10% fetal bovine serum (FBS) 
(Thermo Fisher Scientific; Waltham, Massachusetts, 
USA). Normal epidermal melanocyte cultures were 
obtained from Lonza Biosciences (Basel, Switzerland) and 
cultured according to the manufacturer’s recommendation.
FOXP3 over-expression construct and 
transfection
The plasmid encoding wild-type MYC-tagged 
FOXP3 (pENTR-FOXP3) [43] was obtained from 
Addgene, and the FOXP3 gene subcloned into pcDNA3.2/
V5-DEST using the LR clonase enzyme of the Life 
Technologies Gateway Cloning System. Cells were 
transfected using Lipofectamine 2000 (Life Technologies). 
Stably transfected cells were selected for and maintained 
in medium containing 0.4mg/ml – 1.0mg/ml G418, 
with colonies isolated using cloning cylinders (Merck; 
Whitehouse Station, New Jersey, USA). Knockdown of 
FOXP3 expression was performed using multiple siRNAs, 
the details of which are provided in Supplementary 
Information.
Immunofluorescence
Cells were spun onto glass slides using a Cytospin 
centrifuge (Shandon; Runcorn, UK), then air-dried, fixed 
with methanol at -20°C for 10 minutes, and washed with 
ice-cold PBST (PBS with 0.05% Tween-20). 5% bovine 
serum albumin (BSA) (Sigma; St Louis, Missouri, 
USA) was used for blocking. Staining with anti-FOXP3 
antibody (Ab20034; 2.5µg/ml and Ab10563; 0.8µg/
ml – both Abcam) was followed by incubation with 
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Alexafluor (488 or 555)-conjugated secondary antibodies 
(Life Technologies). Slides were stained with DAPI 
(1:50, Sigma; St Louis, Missouri, USA) for nuclear 
visualization and coverslips added using Vectashield 
(Vector Laboratories; Burlingame, California, USA).
Immunohistochemistry
Immunohistochemistry was performed on tissue 
microarrays constructed from 146 formalin-fixed 
paraffin-embedded (FFPE) stage III and IV melanomas 
after EDTA or citrate buffer (pH 8.0) retrieval using the 
Dako Envision+ kit (Dako; Coopenhagen, Denmark). 
Sections were incubated with 1X protein blocking buffer 
for 10 minutes or one hour at room temperature (Dako), 
followed by primary antibody incubation (Ab20034; 
2.5µg/ml; overnight; and Ab10563; 0.8µg/ml) for one 
hour at room temperature. DAB (3, 3’-diaminobenzidine) 
was used as chromagen (Vector Laboratories), slides were 
counterstained with hematoxylin and scanned using a 
ScanScope XT (Aperio).
Intracellular FOXP3 staining and flow cytometric 
analysis
Staining was performed using anti-FOXP3 antibody 
clone 236A/E7 and the FOXP3 buffer set (eBioscience; 
San Diego, California, USA) following staining with 
Live/Dead® Fixable dead cell stain (Life Technologies) 
at 4°C for 20 minutes. Non-specific staining was reduced 
by incubation with normal mouse serum (Sigma). Stained 
cells were acquired on a FACS Canto II instrument 
(BD Biosciences; San Jose, California, USA), and the 
data analyzed using the FlowJo software (Tree Star Inc; 
Oregon, USA). 
Proliferation assays
Cell counts, MTS assay and CFSE decay 
experiments were performed using standard protocols. 
Details are provided as Supplementary Information.
Clonogenecity assays
Adherent colony formation was assessed by low 
density plating in petri dishes and anchorage independent 
growth assessed using soft agar assays. Details are 
provided as Supplementary Information.
Xenografts
Animal experiments were approved by the Austin 
Health Animal Ethics Committee. Balb/C nude mice, 
4-5 weeks of age were purchased from the Animal 
Resources Centre (ARC, Perth). 9x105 cells were injected 
subcutaneously into the right flank of each mouse in 
100µl of a 1:1 mixture of RF10 with 1.0mg/ml G418 and 
matrigel (BD Biosciences, San Jose, California, USA). 
Tumor size was measured daily and tumor volume was 
calculated as: tumor volume = ½ (width2 x length) [44]. 
The experiment ended when the first tumor in the cohort 
reached the pre-determined endpoint of 1cm3.
Cell cycle analysis
Sub-confluent cells were harvested, washed in cold 
PBS, and resuspended in 500µl propidium iodide solution 
consisting of 50µg/ml of propidium iodide, 0.1% sodium 
citrate, 0.1mg/ml RNAse A and 0.05% of Triton-X (all 
Sigma) in PBS. Cells were incubated overnight at 4°C 
and analyzed by flow cytometry using the FL2 channel. 
FlowJo cell cycle histogram analysis was used to quantify 
the apoptotic cell population.
Quantitative reverse transcriptase-PCR (QPCR)
Total RNA was extracted using the RNeasy mini 
kit (Qiagen, Hilden Germany), and reverse transcribed 
into cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Life Technologies, Carlsbad, California, 
USA). QPCR was performed using the SensiFAST SYBR 
Lo-ROX kit (Bioline, London, UK), and a Stratagene 
Mx3005P thermocycler. Primer sequences are provided in 
Supplementary Table 1.
Gene Expression Microarrays and Data Analysis
Purified RNA was sent to the Australian Genome 
Research Facility for hybridisation to Illumina HT-12 gene 
expression microarrays. Details of the data analysis are 
provided in the Supplementary Information. 
Western Blot
Cells were lysed in RIPA buffer (Sigma) and 
protein concentrations quantified using the BCA protein 
assay (Thermo Scientific). Samples were separated 
using NuPAGE 4-10% BisTris gels (Life Technologies) 
and MES [2-(N-morpholino) ethanesulfonic acid] SDS 
running buffer (Life Technologies). Proteins were 
transfered to PVDF membrane (Milipore) used a semi-dry 
transferblot (Bio-Rad Laboratories, Hercules, California, 
USA). Blocking was performed with 5% skim milk, 
followed by incubation with anti-FOXP3 antibody (236A/
E7 at 2µg/ml from e-Bioscience or anti-GAPDH 1:1000, 
from Sigma) overnight at 4°C. Horseradish peroxidase-
conjugated secondary antibodies (anti-mouse from 
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Sigma St Louis, Missouri, USA or anti-rabbit from New 
England, Boston, Massachusetts, USA) were then added 
for one hour at room temperature. Signal detection was 
performed by incubation of ECL Plus reagent (Amersham 
BioSciences, Amersham, UK) for 5 minutes at room 
temperature followed by imaging using the STORM 840 
v2005 (Amersham).
Statistical analysis
All statistical comparisons were performed using a 
Student’s two-tailed t-test using Prism software (GraphPad 
Software Inc, San Diego, California, USA). A p-value of 
<0.05 was considered statistically significant.
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